Canada-based developer of RNA interference (RNAi) therapeutics, Tekmira Pharmaceuticals, has received notice from the US Food and Drug Administration (FDA) that the TKM-Ebola Phase I healthy volunteer clinical trial has been placed on clinical hold.

The company said that FDA notice applies only to this randomised, single-blind, placebo-controlled TKM-Ebola Phase I trial.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The TKM-Ebola Phase I trial involves single ascending doses and multiple ascending doses of TKM-Ebola.

The trial is designed to evaluate safety, tolerability and pharmacokinetics of administering TKM-Ebola to healthy adult volunteers without administering any steroid pre-medications.

"The trial is designed to evaluate safety, tolerability and pharmacokinetics of administering TKM-Ebola to healthy adult volunteers without administering any steroid pre-medications."

Tekmira Pharmaceuticals president and CEO Mark Murray said: "The FDA has requested additional data related to the mechanism of cytokine release, observed at higher doses, which we believe is well understood, and a protocol modification designed to ensure the safety of healthy volunteer subjects, before we proceed with the multiple ascending dose portion of our TKM-Ebola Phase I trial.

"We will continue our dialogue with the FDA, provided for under our fast track status, in order to advance the development of this important therapeutic agent."

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

TKM-Ebola is an anti-Ebola virus RNAi therapeutic and is currently being developed under a $140 contract with the US Department of Defense’s Medical Countermeasure Systems BioDefense Therapeutics (MCS-BDTX) Joint Product Management Office.

Earlier preclinical studies have shown that when siRNA targeting the Ebola virus and delivered by Tekmira’s LNP technology were used to treat previously infected non-human primates, the result was 100% protection from an otherwise lethal dose of Zaire Ebola virus.

Tekmira received the FDA fast track status in March 2014 for the development of TKM-Ebola.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact